

Merck & Co., Inc.  
UG2A-70  
351 N. Sumneytown Pike  
PO Box 1000  
North Wales, PA 19454-2505



**SUPPLY UPDATE: NASONEX® (mometasone furoate monohydrate)**

September 18, 2015

Dear Pharmaceutical Purchaser:

On behalf of Merck Sharp & Dohme Corp., ("Merck"), a subsidiary of Merck & Co., Inc., I am writing to provide you with an update to the supply status of NASONEX® (mometasone furoate monohydrate).

Due to a manufacturing issue, NASONEX® is out of stock as of September 15, 2015. We currently anticipate having supply available for sale again in November/December 2015.

**Product Information**

How Supplied	Description	NDC NUMBER	Anticipated Availability Date*
NASONEX® (mometasone furoate monohydrate) 50 mcg Nasal Spray	Nasal Spray, 50 mcg† †calculated on the anhydrous basis	00085-1288-01	November/December 2015

\* This date is an estimate and may be subject to change.

Merck continues to accept purchase orders from wholesalers for NASONEX® and all backorders will be filled on a first-in, first-out basis in accordance with Merck's standard practice. Merck product ordering systems will continue to reflect the product status for NASONEX® as "backordered" until all pending backorders are cleared through resupply.

We apologize for the inconvenience that this situation will cause for you and for your customers. We are working to resolve this temporary backorder situation as quickly as possible and will update you as additional information becomes available. If you have any additional questions, please contact your Merck Account Executive or call the Merck Order Management Center at 1-800-MERCK-RX (1-800-637-2579), Monday through Friday, 8:00 AM to 7:00 PM ET.

Sincerely,

A handwritten signature in black ink, appearing to read "Paul J. Bader".

Paul J. Bader, R.Ph.  
Director, Pharmacy & Distribution  
Merck Sharp & Dohme Corp.